The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Self-citationProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“003); a test for Schönfeld residuals revealed no deviations from the proportional hazards assumption, except for a minor departure for constitutional symptoms.(21)”
BackgroundAge-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Self-citationJAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Self-citationCervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationGangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationPassamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationBarbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H. C., Hehlmann, R., Hoffman, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8436 · Cited by 849
Self-citationMutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Self-citationHow to develop a more accurate risk prediction model when there are few events
Pavlou, M., Ambler, G., Seaman, S. R., Guttmann, O., Elliott, P., King, M., & Omar, R. Z. (2015) · BMJ · doi:10.1136/bmj.h3868 · Cited by 664
Tefferi, A., Lasho, T. L., Finke, C. M., Knudson, R. A., Ketterling, R., Hanson, C. H., Maffioli, M., Caramazza, D., Passamonti, F., & Pardanani, A. (2014) · Leukemia · doi:10.1038/leu.2014.3 · Cited by 548
Self-citationBarosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2404914 · Cited by 502
Self-citationPardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.1590 · Cited by 485
Self-citationClinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Rumi, E., Pietra, D., Pascutto, C., Guglielmelli, P., Martínez-Trillos, A., Casetti, I., Colomer, D., Pieri, L., Pratcorona, M., Rotunno, G., et al. (2014) · Blood · doi:10.1182/blood-2014-05-578435 · Cited by 394
Self-citationSafety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Pardanani, A., Laborde, R. R., Lasho, T. L., Finke, C., Begna, K., Al-Kali, A., Hogan, W. J., Litzow, M. R., Leontovich, A., Kowalski, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.71 · Cited by 233
A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression
Marty, C., Lacout, C., Droin, N., Le Couédic, J.-P., Ribrag, V, Solary, E., Vainchenker, W., Villeval, J.-L., & Plo, I. (2013) · Leukemia · doi:10.1038/leu.2013.102 · Cited by 195
Kröger, N., Giorgino, T., Scott, B. L., Ditschkowski, M., Alchalby, H., Cervantes, F., Vannucchi, A., Cazzola, M., Morra, E., Zabelina, T., et al. (2015) · Blood · doi:10.1182/blood-2014-10-608315 · Cited by 186
Self-citationA dynamic prognostic model to predict survival in post–polycythemia vera myelofibrosis
Passamonti, F., Rumi, E., Caramella, M., Elena, C., Arcaini, L., Boveri, E., Curto, C. D., Pietra, D., Vanelli, L., BERNASCONI, P. P., et al. (2008) · Blood · doi:10.1182/blood-2007-11-121434 · Cited by 117
Self-citationDoes ruxolitinib prolong the survival of patients with myelofibrosis?
Cervantes, F., & Pereira, A. (2016) · Blood · doi:10.1182/blood-2016-11-731604 · Cited by 108
Self-citationPassamonti, F., Maffioli, M., Cervantes, F., Vannucchi, A. M., Morra, E., Barbui, T., Caramazza, D., Pieri, L., Rumi, E., Gisslinger, H., et al. (2014) · Blood · doi:10.1182/blood-2013-12-544411 · Cited by 99
Self-citationRotunno, G., Pacilli, A., Artusi, V., Rumi, E., Maffioli, M., Delaini, F., Brogi, G., Fanelli, T., Pancrazzi, A., Pietra, D., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24377 · Cited by 98
Self-citationLeukemic transformation of polycythemia vera: A single center study of 23 patients
Passamonti, F., Rumi, E., Arcaini, L., Castagnola, C., Lunghi, M., Bernasconi, P., Giovanni Della Porta, M., Columbo, N., Pascutto, C., Cazzola, M., et al. (2005) · Cancer · doi:10.1002/cncr.21297 · Cited by 85
Self-citationUpdate from the latest WHO classification of MPNs: a user’s manual
Passamonti, F., & Maffioli, M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.534 · Cited by 67
Self-citationHernández‐Boluda, J. C., Pereira, A., Gómez, M., Boqué, C., Ferrer‐Marín, F., Raya, J. M., García‐Gutiérrez, V., Kerguelen, A., Xicoy, B., Barba, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.101733 · Cited by 58
Recent advances in understanding myelofibrosis and essential thrombocythemia
Vainchenker, W., Constantinescu, S. N., & Plo, I. (2016) · F1000Research · doi:10.12688/f1000research.8081.1 · Cited by 54
Passamonti, F., Mora, B., Toni Giorgino, A., Guglielmelli, P., Cazzola, M., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R. S., Gotlib, J. R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.351 · Cited by 46
Self-citationRozovski, U., Verstovšek, S., Manshouri, T., Dembitz, V., Božinović, K., Newberry, K. J., Zhang, Y., Bove, J. E., Pierce, S. A., Kantarjian, H. M., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.149765 · Cited by 37
Wassie, E. A., Finke, C. M., Gangat, N., Lasho, T. L., Pardanani, A. D., Hanson, C. A., Ketterling, R. P., & Tefferi, A. (2014) · British Journal of Haematology · doi:10.1111/bjh.13260 · Cited by 34
Gowin, K. L., Coakley, M. F., Kosiorek, H., & Mesa, R. A. (2016) · Haematologica · doi:10.3324/haematol.2016.149013 · Cited by 24
Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?
Barosi, G., Zhang, M.-J., & Gale, R. P. (2014) · Leukemia · doi:10.1038/leu.2014.220 · Cited by 23
Mesa, R. A., & Passamonti, F. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159322 · Cited by 16
Self-citationRuxolitinib and survival improvement in patients with myelofibrosis
Passamonti, F., Vannucchi, A. M., Cervantes, F., Harrison, C. N., Morra, E., Kantarjian, H. M., & Verstovšek, S. (2014) · Leukemia · doi:10.1038/leu.2014.282 · Cited by 13
Self-citation
Cited by
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
Grinfeld, J., Nangalia, J., Baxter, E. J., Wedge, D. C., Angelopoulos, N., Cantrill, R., Godfrey, A. L., Papaemmanuil, E., Gundem, G., MacLean, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716614 · Cited by 631
Self-citationBarbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., Verstovsek, S., Mesa, R., Kiladjian, J.-J., Hehlmann, R., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0077-1 · Cited by 566
Self-citationPrimary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
Tefferi, A. (2023) · American Journal of Hematology · doi:10.1002/ajh.26857 · Cited by 305
Grabek, J., Straube, J., Bywater, M., & Lane, S. W. (2020) · Cells · doi:10.3390/cells9081901 · Cited by 53
Metadata
- Authors
- Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Caramazza, D., Merli, M., Pietra, D., Casalone, R., Rotunno, G., Barbui, T., Cazzola, M., & Vannucchi, A. M.
- Venue
- Leukemia
- Published
- 2017-05-31
- Volume
- 31
- Issue
- 12
- Pages
- 2726-2731
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2620415343
- Cited by
- 348
- References
- 35
- FWCI
- 14.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.